Clinical trials: Migraine, completed
Vestibular Migraine, Migrainous Vertigo
Rizatriptan for Episodic Dizziness in Vestibular Migraine
Suffering from dizzy spells and migraine headaches? Vestibular Migraine (VM), a newly recognized type of migraine that causes bouts of dizziness.
- Trial name
- NCT02447991
- Testing
- Rizatriptan
- Where
- 3 sites in United States
- Volunteers
- 223 people
- Sponsor
- Robert W. Baloh
Migraine
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home.
- Trial name
- NCT04355117
- Testing
- Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period.
- Trial name
- NCT01125774
- Testing
- Telcagepant
- Volunteers
- 4,548 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Migraine
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
This is a multicenter, open-label, non-randomized, parallel-group, single dose study. This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with…
- Trial name
- NCT03040479
- Testing
- lasmiditan 200 mg
- Where
- 3 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-2 (NCT02614196)
- Testing
- Galcanezumab
- Where
- 113 sites in United States, Argentina and 10 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Migraine, Acute Treatment of Migraine
Nerivio Efficacy by Time of Treatment Onset
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine.
- Trial name
- NCT06976723
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 55,261 people
- Sponsor
- Theranica
Migraine
Neurophysiology of Prophylactic Treatment in Migraine
This study aims to improve the pathophysiological understanding of migraine in in a longitudinal observational study investigating changes of established neurophysiological and imaging parameters in line with changes of the…
- Trial name
- NCT04019496
- Testing
- antibodies against calcitonin-gene related peptide or its receptor
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
High Blood Pressure, Migraine Headaches
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Trial name
- NCT00960245
- Testing
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sandoz
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited.
- Trial name
- NCT07487701
- Testing
- Nerivio REN device
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Theranica
Migraine Headache, Aura
Staccato Prochlorperazine in Migraine (Out Patient)
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients…
- Trial name
- NCT00422812
- Testing
- Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine Headache
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
- Trial name
- NCT01462812
- Testing
- Sumatriptan
- Where
- 15 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Migraine
Tampa Kinesiophobia Scale Modified for Headache
Tampa Kinesiophobia Scale is a scale that has been validated and reliable in individuals with low back pain in the Turkish population and evaluates fear of movement due to the risk of triggering pain.
- Trial name
- Kinesiophobia (NCT06857357)
- Testing
- Questionnaires
- Where
- 14 sites in Cyprus, Turkey (Türkiye)
- Volunteers
- 329 people
- Sponsor
- Bozok University
Menstrual Migraine
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
The purpose of this study is to (1) evaluate pain-free efficacy of Treximet™ following treatment of menstrual migraine, (2) investigate levels of Calcitonin gene-related peptide (CGRP), estrogen, cortisol, vasoactive intestinal…
- Trial name
- NCT01329562
- Testing
- Treximet
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Cady, Roger, M.D.
Migraine Disorders
BI 44370 TA in Acute Migraine Attack
The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared…
- Trial name
- NCT00751803
- Testing
- BI 44370 TA Low Dose, Eletriptan, BI 44370 TA Medium Dose
- Where
- 52 sites in Belgium, El Salvador and 7 more
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine…
- Trial name
- NP101-009 (NCT00806546)
- Testing
- NP101
- Where
- 31 sites in United States
- Volunteers
- 514 people
- Sponsor
- NuPathe Inc.
Migraine With or Without Aura
An Acute Migraine Factorial Study
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT06245902)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.